You are here: Industry Insights > Market News > Rare disease biotech Rallybio sets terms for $81 million IPO

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Rare disease biotech Rallybio sets terms for $81 million IPO

firstwordpharmaJuly 23, 2021

Tag: Rallybio , IPO , RLYB211

Favorites

Rallybio plans to raise $81 million in its initial public offering by offering 5.8 million shares at a price range of $13 to $15, as reported by NASDAQ.

The company is currently advancing its lead program, RLYB211, in a Phase I/II trial for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

RLYB211 is a polyclonal anti-HPA-1a antibody and is expected to report data from its Phase I/II trial this month.

The company also has four preclinical programs, one of which, RLBY212, is also being developed for the treatment of FNAIT, and two of which are being developed to treat complement dysregulation diseases.

Previous:TGA approves Pfizer COVID-19 vaccine for 12 to 15-year-olds

Next:Acticor Biotech Announces the Completion of Enrollment in its GARDEN Clinical Trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Rare disease biotech Rallybio sets terms for $81 million IPO

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may like
More>>

Rare disease biotech Rallybio sets terms for $81 million IPO

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>